AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25933197 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive Oil (OO) 3 g/day
Number of subjects: 42
Study 25933197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 3 g/day
Number of subjects: 42
Study 25933197 — intervention group
Group type: COMPARATOR
Intervention: Control (naive)
Number of subjects: 42
Study 24089026 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine lithotomy position (group A)
Number of subjects: 109
Study 24089026 — intervention group
Group type: COMPARATOR
Intervention: Prone position (group B)
Number of subjects: 109
Study 21129866 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous bisphosphonates
Number of subjects: 0
Study 21129866 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene and denosumab
Number of subjects: 0
Study 21129866 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 21129866 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 0
Study 21129866 — intervention group
Group type: COMPARATOR
Intervention: Bone mineral density (BMD) testing by dual energy X-ray absorptiometry (DXA)
Number of subjects: 0
Study 21129866 — intervention group
Group type: COMPARATOR
Intervention: Forearm DXA
Number of subjects: 0
Study 21129866 — intervention group
Group type: COMPARATOR
Intervention: FRAX or another risk calculator
Number of subjects: 0
Study 19268266 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmectite (6 g/day for children 1-12 months; 12 g/day for children 13-36 months)
Number of subjects: 602
Study 19268266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 19268266 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmectite
Number of subjects: 602
Study 17316925 — intervention group
Group type: EXPERIMENTAL
Intervention: 17DD vaccine
Number of subjects: 0
Study 17316925 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO 17D-213/77 vaccine
Number of subjects: 0
Study 17316925 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of yellow fever and measles-mumps-rubella vaccines
Number of subjects: 0
Study 17316925 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibodies
Number of subjects: 0
Study 15308998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 1356
Study 15308998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 1356
Study 15308998 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 1356
Study 15308998 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 1356
Study 11672549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen Lo
Number of subjects: 2894
Study 11672549 — intervention group
Group type: COMPARATOR
Intervention: Loestrin Fe 1/20
Number of subjects: 2894
Study 9877264 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 5 microg/kg/day
Number of subjects: 16
Study 9877264 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 10 microg/kg/day
Number of subjects: 16
Study 9877264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8066937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 85
Study 8066937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 2662884 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium‐meglumine ioxaglate
Number of subjects: 20
Study 2662884 — intervention group
Group type: COMPARATOR
Intervention: iopromide
Number of subjects: 20
Study 2662884 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium‐meglumine ioxaglate and iopromide
Number of subjects: 20
Study 30578396 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical intervention group (received a musical intervention and visual deprivation during the first 30 minutes of each NIV session)
Number of subjects: 113
Study 30578396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory deprivation group (wore insulating headphones and visual deprivation during the first 30 minutes of each NIV session)
Number of subjects: 113
Study 30578396 — intervention group
Group type: COMPARATOR
Intervention: Control group (received NIV as routinely performed)
Number of subjects: 113
Study 27838777 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin 6 mg orally on day #2 of the chemotherapy cycle (post-paclitaxel)
Number of subjects: 30
Study 27838777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25520278 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at bilateral ST36 and PC6 points
Number of subjects: 40
Study 25520278 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia without EA stimulation
Number of subjects: 40
Study 22921765 — intervention group
Group type: EXPERIMENTAL
Intervention: DTMS after brief exposure to the traumatic event with the script‐driven imagery procedure
Number of subjects: 30
Study 22921765 — intervention group
Group type: COMPARATOR
Intervention: DTMS after brief exposure to a non‐traumatic event
Number of subjects: 30
Study 22921765 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation after brief exposure to the traumatic event
Number of subjects: 30
Study 21963002 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified primary care management
Number of subjects: 1573
Study 21963002 — intervention group
Group type: COMPARATOR
Intervention: Current best practice (non-stratified care)
Number of subjects: 1573
Study 18828141 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM
Number of subjects: 157
Study 18828141 — intervention group
Group type: COMPARATOR
Intervention: Control (usual curriculum)
Number of subjects: 157
Study 17122137 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 18
Study 17122137 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Number of subjects: 18
Study 17122137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15579782 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg androstenedione t.i.d. for 28 days
Number of subjects: 20
Study 11736743 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula (pHF)
Number of subjects: 72
Study 11736743 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed (BF)
Number of subjects: 72
Study 11736743 — intervention group
Group type: COMPARATOR
Intervention: All groups (pHF, eHF, BF)
Number of subjects: 72
Study 9015054 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic-covered stent placement
Number of subjects: 60
Study 9015054 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered stent placement
Number of subjects: 60
Study 9015054 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 60
Study 8095980 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (BW-02 study)
Number of subjects: 0
Study 8095980 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ACTG-002 study)
Number of subjects: 0
Study 8095980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 2946277 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 monthly doses of 2 micrograms vaccine mixed with adjuvant subcutaneously (Institut Pasteur Production‐Hevac B)
Number of subjects: 125
Study 2946277 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of 2 micrograms non‐adjuvated vaccine intradermally given 1 month apart
Number of subjects: 125
Study 31548184 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Number of subjects: 199
Study 29452816 — intervention group
Group type: COMPARATOR
Intervention: Low-flow 100% oxygen at 0.2 litres kg-1 min-1 (Control)
Number of subjects: 60
Study 29452816 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE 100% oxygen at 2 litres kg-1 min-1
Number of subjects: 60
Study 29452816 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE 30% oxygen at 2 litres kg-1 min-1
Number of subjects: 60
Study 27382591 — intervention group
Group type: EXPERIMENTAL
Intervention: Orem's self-care model-based training (8 sessions of 2 hours each)
Number of subjects: 64
Study 27382591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 24387842 — intervention group
Group type: EXPERIMENTAL
Intervention: Novamin 18 AAs (2 mL/kg/h)
Number of subjects: 60
Study 24387842 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (0.5 mg/kg)
Number of subjects: 60
Study 24387842 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (1 mg/kg)
Number of subjects: 60
Study 22542094 — intervention group
Group type: COMPARATOR
Intervention: Intervention from randomized trials (NET‐PD FS1 and FS‐TOO)
Number of subjects: 413
Study 19631856 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment delivered after occurrence of dental trauma
Number of subjects: 0
Study 17435407 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin rehabilitation massage therapy (SRMT) for 3 months
Number of subjects: 18
Study 17435407 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin rehabilitation massage therapy (SRMT)
Number of subjects: 18
Study 15561449 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA gum
Number of subjects: 439
Study 15561449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 439
Study 15561449 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 439
Study 11956968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 555
Study 11956968 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 555
Study 9863744 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 20
Study 9863744 — intervention group
Group type: COMPARATOR
Intervention: Uncoated aspirin
Number of subjects: 20
Study 8567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-triathlon DLCO
Number of subjects: 8
Study 8567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-triathlon DLCO
Number of subjects: 8
Study 8567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-triathlon KCO
Number of subjects: 8
Study 8567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-triathlon KCO
Number of subjects: 8
Study 8567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-triathlon mean lung density
Number of subjects: 8
Study 8567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-triathlon mean lung density
Number of subjects: 8
Study 8567566 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-triathlon number of polygonal and linear opacities
Number of subjects: 8
Study 1637604 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate in propylene glycol (EtoPG)
Number of subjects: 12
Study 1637604 — intervention group
Group type: COMPARATOR
Intervention: Etomidate in lipid emulsion (EtoLip)
Number of subjects: 12
Study 6375703 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 350 (Omnipaque)
Number of subjects: 25
Study 6375703 — intervention group
Group type: COMPARATOR
Intervention: Urografin 370
Number of subjects: 25
Study 31154313 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing peer reviewers with a summary of registered, pre‐specified primary trial outcomes during the intervention phase.
Number of subjects: 0
Study 31154313 — intervention group
Group type: COMPARATOR
Intervention: Control phase where peer reviewers do not receive registry information.
Number of subjects: 0
Study 29923299 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 3 days
Number of subjects: 7
Study 29923299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 26685074 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP-guided hydration group (n = 132)
Number of subjects: 264
Study 26685074 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration group (n = 132)
Number of subjects: 264
Study 22101228 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention using Motivational Interviewing techniques
Number of subjects: 632
Study 22101228 — intervention group
Group type: COMPARATOR
Intervention: Minimal mail-out intervention
Number of subjects: 632
Study 20030435 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 single-injection formulation
Number of subjects: 253
Study 18930254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat vegan diet
Number of subjects: 9
Study 18930254 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy beverage
Number of subjects: 9
Study 18930254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplement
Number of subjects: 9
Study 18930254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation
Number of subjects: 9
Study 15879163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 10
Study 15879163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15879163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 10
Study 14654762 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic-based regimen (usually bendroflumethiazide)
Number of subjects: 1283
Study 14654762 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor regimen (usually lisinopril)
Number of subjects: 1283
Study 14654762 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (combined diuretic and ACE inhibitor)
Number of subjects: 1283
Study 11127968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A; specific dosage and duration not available
Number of subjects: 0
Study 11127968 — intervention group
Group type: COMPARATOR
Intervention: Observational studies and randomized controlled trials
Number of subjects: 0
Study 8085494 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire on sexuality aspects
Number of subjects: 240
Study 2511939 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice on early mobilisation
Number of subjects: 247
Study 2511939 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 247
Study 2511939 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 247
Study 2511939 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice or physiotherapy
Number of subjects: 247
Study 836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen freezing method
Number of subjects: 16
Study 836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryokwik freezing method
Number of subjects: 16
Study 836153 — intervention group
Group type: COMPARATOR
Intervention: Both methods of freezing (Liquid nitrogen and Cryokwik)
Number of subjects: 16
Study 31353172 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal advancement surgery with sagittal split ramus osteotomy (SSRO)
Number of subjects: 18
Study 31353172 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal advancement surgery with mandibular distraction osteogenesis (MDO)
Number of subjects: 18
Study 31353172 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 18
Study 31216388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure injury observed within the first 36 hours of hospital admission
Number of subjects: 1047
Study 31216388 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, multiple comorbidities, and living in an aged care facility
Number of subjects: 1047
Study 28736413 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent mentor (PM) intervention built on community partnerships
Number of subjects: 329
Study 28736413 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent mentor (PM) intervention
Number of subjects: 329
Study 24368725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐day intravenous infusion of creatine phosphate (CP) after PCI
Number of subjects: 400
Study 24368725 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 400
Study 23734858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 weeks
Number of subjects: 202
Study 23734858 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) for 16 weeks
Number of subjects: 202
Study 23734858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT and CM for 16 weeks
Number of subjects: 202
Study 23734858 — intervention group
Group type: COMPARATOR
Intervention: No additional behavioral treatment (NT) for 16 weeks
Number of subjects: 202
Study 20700742 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable cervical tourniquet (group 1)
Number of subjects: 44
Study 20700742 — intervention group
Group type: COMPARATOR
Intervention: No absorbable cervical tourniquet (group 2)
Number of subjects: 44
Study 17885079 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology assessment by 3 experienced hematopathologists for 16 different morphologic features and overall diagnosis according to WHO classification.
Number of subjects: 370
Study 17885079 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulin grade assessment.
Number of subjects: 370
Study 17885079 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of histopathological features.
Number of subjects: 370
Study 17885079 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of clinical and laboratory features at presentation, JAK2 status, survival, thrombosis, major hemorrhage, or myelofibrotic transformation between patients labeled as 'prefibrotic myelofibrosis' or 'true ET'.
Number of subjects: 370
Study 16584506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline therapy (0.5-1 mg twice per week) for 12 weeks
Number of subjects: 15
Study 16584506 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 15
Study 14597512 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of patching per day
Number of subjects: 175
Study 14597512 — intervention group
Group type: COMPARATOR
Intervention: Full-time patching (all hours or all but 1 hour per day)
Number of subjects: 175
Study 11038977 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs for nourishing the kidney‐yin, invigorating blood circulation and removing blood stasis
Number of subjects: 35
Study 11038977 — intervention group
Group type: COMPARATOR
Intervention: Euglucon and other routine drugs
Number of subjects: 35
Study 8769908 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance directive videotape
Number of subjects: 36
Study 8769908 — intervention group
Group type: COMPARATOR
Intervention: Health-relative videotape
Number of subjects: 36
Study 8383548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Number of subjects: 190
Study 8383548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 3948126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubidazone 450 mg/m2
Number of subjects: 34
Study 3948126 — intervention group
Group type: COMPARATOR
Intervention: Rubidazone 300 mg/m2
Number of subjects: 34
Study 29728551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer (HR)
Number of subjects: 66
Study 29728551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer (VFR) with thickness of 1.5 mm
Number of subjects: 66
Study 29728551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer (VFR) with thickness of 1 mm
Number of subjects: 66
Study 27523625 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail without distal locking screw (Unlocking Group - UG)
Number of subjects: 333
Study 27523625 — intervention group
Group type: COMPARATOR
Intervention: Proximal femoral nail with distal locking screw (Locking Group - LG)
Number of subjects: 333
Study 24531549 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (serotonin receptor type 1A agonist) prior to levodopa administration
Number of subjects: 0
Study 24531549 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (identical doses)
Number of subjects: 0
Study 24531549 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 22133521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality foster care (FCG)
Number of subjects: 0
Study 22133521 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAUG)
Number of subjects: 0
Study 22133521 — intervention group
Group type: EXPERIMENTAL
Intervention: No plasticity alleles
Number of subjects: 0
Study 20541178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster II (higher neuroticism, lower control over CB symptoms)
Number of subjects: 68
Study 20541178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster II (higher rates of comorbid anxiety disorders and cluster B personality disorders)
Number of subjects: 68
Study 20541178 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 68
Study 18702965 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (rosuvastatin 10 or 20 mg, atorvastatin 10 or 20 mg, simvastatin 20 or 40 mg)
Number of subjects: 0
Study 18702965 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 0
Study 15936647 — intervention group
Group type: EXPERIMENTAL
Intervention: Black currant seed oil (3 g/day)
Number of subjects: 15
Study 15936647 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (2.8 g/day)
Number of subjects: 15
Study 14616666 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillotomy
Number of subjects: 14
Study 14616666 — intervention group
Group type: COMPARATOR
Intervention: Coblation tonsillectomy
Number of subjects: 14
Study 11228758 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 165
Study 11228758 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) and Glibenclamide (G)
Number of subjects: 165
Study 11228758 — intervention group
Group type: EXPERIMENTAL
Intervention: High proinsulin levels
Number of subjects: 165
Study 11228758 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-stimulated glucose (net AUC)
Number of subjects: 165
Study 11228758 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinsulin change after therapy
Number of subjects: 165
Study 8759264 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% drops
Number of subjects: 12
Study 8759264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual timolol
Number of subjects: 12